The fluorinated pyrimidines were first introduced as cancer chemotherapeutic drugs in 1957 by Heidelberger.3 The first of these, fluorouracil (FU), has received rather widespread usage and is now available on the market. Numerous other drugs in the group have been developed both by alterations of the pyrimidine structure and by using other members of the halogen family. Of these newer drugs, 5-fluorodeoxyuridine (FUDR) has shown the most promise and has been used most widely in clinical trials. Pharmacologic studies have shown that FUDR has about one half the toxicity of the parent FU; however, indications are that quantitatively it has only one half of the therapeutic effectiveness of the parent drug. In studies by Curreri and Ansfield1 the therapeutic effectiveness of this group of drugs against carcinoma of the alimentary tract, especially carcinoma of the large bowel, was demonstrated. The studies also indicated that FUDR is more effective
The Use of 5-Fluorodeoxy uridine (FUDR) as a Surgical Adjuvant in Carcinoma of the Stomach and Colorectum. Arch Surg. 1963;86(6):926–931. doi:10.1001/archsurg.1963.01310120044008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: